Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression

International Journal of Clinical Practice

Volumn 61, Issue 8, 2007, Pages 1337-1348

  Shelton, R C ^a   Prakash, A ^b   Mallinckrodt, C H ^b   Wohlreich, M M ^b   Raskin, J ^b   Robinson, M J ^b   Detke, M J ^b,c,d,e  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MCLEAN HOSPITAL   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DULOXETINE; PLACEBO;

ARTICLE; CLINICAL TRIAL; DATA ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EMOTION; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; META ANALYSIS; OUTPATIENT; OUTPATIENT CARE; PATIENT SATISFACTION; PRIORITY JOURNAL; RATING SCALE; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; COHORT STUDIES; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; THIOPHENES; TREATMENT OUTCOME;

EID: 34447321014     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01444.x     Document Type: Article

References (43)

1. Shelton RC, Andorn AC, Mallinckrodt CH et al. Evidence for the efficacy of duloxetine in treating mild, moderate, and severe depression. Int Clin Psychopharmacol 2007 (in press).
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Washington, DC : American Psychiatric Association, 1994.
3. Kessler RC, Berglund P, Demler O et al. National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003 289 : 3095 105.
4. Blair-West GW, Cantor CH, Mellsop GW, Eyeson-Annan ML. Lifetime suicide risk in major depression: sex and age determinants. J Affect Disord 1999 55 : 171 8.
5. Paykel ES, Ramana R, Cooper Z et al. Residual symptoms after partial remission: an important outcome in depression. Psychol Med 1999 25 : 1171 80.
6. Judd LL, Paulus MJ, Schettler PJ et al. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? Am J Psychiatry 2000 157 : 1501 4.
7. Kennedy S, McIntyre R, Fallu A, Lam R. Pharmacotherapy to sustain the fully remitted state. J Psychiatry Neurosci 2002 27 : 269 80.
8. Keller MB. Past, present, and future directions for defining optimal treatment outcome in depression: remission and beyond. JAMA 2003 289 : 3152 60.
9. McIntyre RS, O'Donovan C. The human cost of not achieving remission in depression. Can J Psychiatry 2004 49 (Suppl. 1 S10 6.
10. Sokero TP, Melartin TK, Rytsala HJ et al. Prospective study of risk factors for attempted suicide among patients with DSM-IV major depressive disorder. Br J Psychiatry 2005 186 : 314 8.
11. Ruhe HG, Huyser J, Swinkels JA, Schene AH. Dose escalation for insufficient response to standard-dose selective serotonin reuptake inhibitors in major depressive disorder: systematic review. Br J Psychiatry 2006 189 : 309 16.
12. Baker CB, Woods SW. Is there a SSRI dose response in treating major depression? The case for re-analysis of current data and for enhancing future study design. Depress Anxiety 2003 17 : 10 8.
13. Detke MJ, Lu Y, Goldstein DJ et al. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002 63 : 308 15.
14. Detke MJ, Lu Y, Goldstein DJ et al. Duloxetine 60 mg once daily dosing vs. placebo in the acute treatment of major depression. J Psychiatr Res 2002 36 : 383 90.
15. Endicott J, Cohen J, Nee J et al. Hamilton Depression Rating Scale. Extracted from regular and change versions of the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry 1981 38 : 98 103.
16. Kasper S. Efficacy of antidepressants in the treatment of severe depression: the place of mirtazapine. J Clin Psychopharmacol 1997 17 (Suppl. 1 S19 28.
17. Kasper S, Zivkov M, Roes KC, Pols AG. Pharmacological treatment of severely depressed patients: a meta-analysis comparing efficacy of mirtazapine and amitriptyline. Eur Neuropsychopharmacol 1997 7 : 115 24.
18. Versiani M, Moreno R, Ramakers-van Moorsel CJ, Schutte AJ Comparative Efficacy Antidepressants Study Group. Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients. CNS Drugs 2005 19 : 137 46.
19. Brannan SK, Mallinckrodt CH, Brown EB et al. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J Psychiatr Res 2005 39 : 43 53.
20. Nierenberg AA, Greist JH, Mallinckrodt CH et al. Duloxetine vs. escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. Curr Med Res Opin 2007 23 : 401 16.
21. Raskin J, Wiltse C, Siegal A et al. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry 2007 164 : 900 909.
22. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960 23 : 56 62.
23. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979 134 : 382 9.
24. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. Rockville, MD : National Institutes of Mental Health, 1976.
25. Folstein MF, Folstein SE, McHugh PR. 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975 12 : 189 98.
26. Gibbons RD, Clark DC, Kupfer DJ. Exactly what does the Hamilton Depression Rating Scale measure? J Psychiatr Res 1993 27 : 259 73.
27. Faries D, Herrera J, Rayamajhi J et al. The responsiveness of the Hamilton Depression Rating Scale. J Psychiatr Res 2000 34 : 3 10.
28. Cleary M, Guy W. Factor analysis of the Hamilton depression scale. Drugs Exp Clin Res 1977 1 : 115 20.
29. Maier W, Philipp M. Improving the assessment of severity of depressive states: a reduction of the Hamilton Depression Scale. Pharmacopsychiatry 1985 18 : 114 5.
30. Khan A, Detke M, Khan SR et al. Placebo response and antidepressant clinical trial outcome. J Nerv Ment Dis 2003 191 : 211 8.
31. Ohayon MM, Roth T. Place of chronic insomnia in the course of depressive and anxiety disorders. J Psychiatr Res 2003 37 : 9 15.
32. Fava M. Daytime sleepiness and insomnia as correlates of depression. J Clin Psychiatry 2004 65 (Suppl. 16 27 32.
33. Tranter R, O'Donovan C, Chandarana P, Kennedy S. Prevalence and outcome of partial remission in depression. J Psychiatry Neurosci 2002 27 : 241 7.
34. Menza M, Marin H, Opper RS. Residual symptoms in depression: can treatment be symptom-specific? J Clin Psychiatry 2003 64 : 516 23.
35. Nierenberg AA, Keefe BR, Leslie VC et al. Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry 1999 60 : 221 5.
36. Reynolds CF III., Frank E, Houck PR et al. Which elderly patients with remitted depression remain well with continued interpersonal psychotherapy after discontinuation of antidepressant medication. Am J Psychiatry 1997 154 : 958 62.
37. Brannan SK, Mallinckrodt CH, Detke MJ et al. Onset of action for duloxetine 60 mg once daily: double-blind, placebo-controlled studies. J Psychiatr Res 2005 39 : 161 72.
38. Hirschfeld RM, Mallinckrodt C, Lee TC, Detke MJ. Time course of depression-symptom improvement during treatment with duloxetine. Depress Anxiety 2005 21 : 170 7.
39. Katz MM, Tekell JL, Bowden CL et al. Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression. Neuropsychopharmacology 2004 29 : 566 79.
40. Papakostas GI, Petersen T, Sklarsky KG et al. Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder. Psychiatry Res 2007 149 : 195 200.
41. Greist J, McNamara RK, Mallinckrodt CH et al. Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine. Clin Ther 2004 6 : 1446 55.
42. Lipsitz J, Williams JBW. Assessment of severe depressive disorders. In : Grunhaus L, Greden JF, eds. Severe Depressive Disorders. Washington, DC : American Psychiatric Press, 1994 : 1 22.
43. Nelson JC, Clary CM, Leon AC, Schneider LS. Symptoms of late-life depression frequency and change during treatment. Am J Geriatr Psychiatry 2005 13 : 520 6.